Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05084937

Celiac Disease in Childhood-Adulthood Transition

Aims of this study are to evaluate adolescents with celiac disease during their transition from pediatrics to adult care, and to develop better healthcare follow-up practices.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

13 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kuopio University Hospital, Kuopio, Finland

Loading trial locations.

About this study

Celiac disease is one of the most common chronic gastrointestinal diseases affecting 1-3% of population worldwide. It is treated with life-long and strict gluten-free diet. When dietary treatment is successful, prognosis of pediatric patients seems to be excellent whereas ongoing predisposition to gluten may increase the risk even to permanent complications. However, gluten-free diet may cause burden and restrictions in everyday life impairing quality of life. Regular follow-up is recommended to support the treatment and to detect early possible comorbidities and complications, but, in practice, patients are often lost to follow-up. Studies about the significance of follow-up and its optimal implementation are scarce. Pediatric patients form a special group here as they may not even remember the reason for the diagnosis if it was set in early childhood, and the education about the disease and its treatment are often given primarily to the caregivers. Responsibility of the treatment shifts to patients themselves in adolescence at the same time with other significant changes in life and they have more often challenges with gluten-free diet than other patients. Despite this, studies about the transition from pediatrics to adult-care are very few.

This study evaluates 13-19 years old patients diagnosed with celiac disease in childhood (<16 years of age) and compares them to adolescents without celiac disease in selected variables. Study focuses on healthcare follow-up practices and pilot a CeliCAT transition form in a randomized, controlled study design. The main hypothesis is that structured follow-up and transition of pediatric patients to adult care predicts better health, quality of life and adherence to the dietary treatment later in life. Data is collected with physical examination, questionnaires and with blood and urine samples. Follow-up is arranged at one and three years from the first visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • verified celiac disease diagnosis in childhood (<16 years of age)
  • age 13-19 years at recruitment
  • Finnish-speaking

Exclusion criteria

  • disease or condition preventing the completing of the study questionnaire

Inclusion criteria

for controls

  • no celiac disease diagnosis
  • age 13-19 years at recruitment
  • Finnish-speaking

Treatment and study plan

CeliCAT form

Other

Systematic summary to support transition

Primary outcomes

  1. Adherence to a gluten-free diet

    Time frame: At the onset of the study

    Assessed with questionnaire, celiac autoantibodies and urine GIP

  2. Change in adherence to a gluten-free diet

    Time frame: After 1 and 3 years

    Assessed with questionnaire, celiac autoantibodies and urine GIP

  3. Transition readiness

    Time frame: At the onset of the study

    Assessed with questionnaire

  4. Change in transition readiness

    Time frame: After 1 and 3 years

    Assessed with questionnaire

Secondary outcomes

  1. General health and health concerns

    Time frame: At the onset of the study

    Assessed with questionnaire

  2. Change in general health and health concerns

    Time frame: After 1 and 3 years

    Assessed with questionnaire

  3. Symptoms

    Time frame: At the onset of the study

    Assessed with questionnaire

  4. Change in symptoms

    Time frame: After 1 and 3 years

    Assessed with questionnaire

  5. Quality of life

    Time frame: At the onset of the study

    Assessed with questionnaire

  6. Change in quality of life

    Time frame: After 1 and 3 years

    Assessed with questionnaire

  7. Costs

    Time frame: At the onset of the study

    Assessed with questionnaire

  8. Abnormalities in follow-up laboratory evaluations

    Time frame: At the onset of the study

    Assessed with blood sample

  9. Abnormalities in physical examination

    Time frame: At the onset of the study

    Assessed with medical examination

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Collaborators

  • Kuopio University Hospital
  • Seinajoki Central Hospital
  • South Carelia Central Hospital
  • Tampere University
  • Turku University Hospital

Registry information

Official study title

Celiac Disease in Childhood-Adulthood Transition (CeliCAT)

Acronym: CeliCAT

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Oct 20, 2021
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.